华东医药：目前公司吲哚布芬晶型专利状态仍为有效

Core Viewpoint - East China Pharmaceutical (华东医药) is actively pursuing legal action against Zhejiang Tongwu Biopharmaceutical Co., Ltd. for patent infringement related to its indobufen crystal form patent, which remains valid [1] Group 1: Patent Status and Legal Actions - The company's patent for "Indobufen Crystal Form D and its preparation method" (Patent No: ZL202211596913.5) is still effective [1] - The company has filed an administrative ruling request with the Hangzhou Intellectual Property Bureau against Zhejiang Tongwu for patent infringement, which resulted in a ruling to cease infringement [1] - During the first instance of the administrative litigation, Zhejiang Tongwu disclosed that its raw material source is from a company in Sichuan, leading to the Hangzhou Intellectual Property Bureau revoking its previous ruling due to new facts [1] Group 2: Ongoing Legal Proceedings - The administrative ruling application process regarding the raw material source from the Sichuan company is currently under normal acceptance [1] - The infringement fact remains unchanged, and the company will continue to monitor the case's progress and take necessary legal measures to protect its rights [1]